DOCSLIB.ORG

Boletín Fármacos: Ética Y Derecho

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Boletín Fármacos: Ética Y Derecho Boletín Fármacos: Ética y Derecho Boletín electrónico para fomentar el acceso y el uso adecuado de medicamentos http://www.saludyfarmacos.org/boletin-farmacos/ Publicado por Salud y Fármacos Volumen 23, número 3, agosto 2020 Boletín Fármacos es un boletín electrónico de la organización Salud y Fármacos que se publica cuatro veces al año: el último día de cada uno de los siguientes meses: febrero, mayo, agosto y noviembre. Editores Equipo de Traductores Núria Homedes Beguer, EE.UU. Núria Homedes, EE UU Antonio Ugalde, EE.UU. Enrique Muñoz Soler, España Antonio Ugalde, EE.UU. Asesores de Ética Maria Cristina Latorre, Colombia Claudio Lorenzo, Brasil Andrea Carolina Reyes Rojas, Colombia Jan Helge Solbakk, Noruega Jaime Escobar, Colombia Editores Asociados Corina Bontempo Duca de Freitas, Brasil Asesores en Ensayos Clínicos Albin Chaves, Costa Rica Juan Erviti, España Hernán Collado, Costa Rica Gianni Tognoni, Italia Francisco Debesa García, Cuba Emma Verástegui, México Anahí Dresser, México Claude Verges, Panamá José Humberto Duque, Colombia Albert Figueras, España Asesor en Publicidad y Promoción Sergio Gonorazky, Argentina Adriane Fugh-Berman Alejandro Goyret, Uruguay Eduardo Hernández, México Corresponsales Luis Justo, Argentina Rafaela Sierra, Centro América Óscar Lanza, Bolivia Steven Orozco Arcila, Colombia René Leyva, México Raquel Abrantes, Brasil Duilio Fuentes, Perú Benito Marchand, Ecuador Webmaster Gabriela Minaya, Perú People Walking Bruno Schlemper Junior, Brasil Xavier Seuba, España Federico Tobar, Panamá Francisco Rossi, Colombia Boletín Fármacos solicita comunicaciones, noticias, y artículos de investigación sobre cualquier tema relacionado con el acceso y uso de medicamentos; incluyendo temas de farmacovigilancia; políticas de medicamentos; ensayos clínicos; ética y medicamentos; dispensación y farmacia; comportamiento de la industria; prácticas recomendables y prácticas cuestionadas de uso y promoción de medicamentos. También publica noticias sobre congresos y talleres que se vayan a celebrar o se hayan celebrado sobre el uso adecuado de medicamentos. Boletín Fármacos incluye una sección en la que se presentan síntesis de artículos publicados sobre estos temas y una sección bibliográfica de libros. Los materiales que se envíen para publicarse en uno de los números deben ser recibidos con treinta días de anticipación a su publicación. El envío debe hacerse preferiblemente por correo electrónico, a ser posible en Word o en RTF, a Núria Homedes ([email protected]). Para la revisión de libros enviar un ejemplar a Antonio Ugalde, 1808 Gelncliff Dr Austin Tx 78704, EE.UU. Teléfono: (202) 999 9079 Índice Boletín Fármacos: Ética y Derecho Ética Investigaciones COVID-19 y remdesivir: la construcción de un éxito de ventas durante una pandemia Ugalde A, Reyes A, Homedes N 1 Gastos en cabildeo, contribuciones a las campañas y Sistema de Salud – siga el dinero Robert Steinbrook 15 Las organizaciones canadienses que producen guías de práctica clínica e informes de conflictos de interés financiero: un estudio descriptivo Elder K, Turner KA, Cosgrove L, Lexchin J et al 18 Relación entre los conflictos de interés financiero y el éxito académico de los profesores junior de hematología y oncología. Fought AJ, Davis AA, Shaw MM, Prasad V, Kamath SD 19 Influencia commercial y Covid-19 Moynihan R et al. 19 En nombre de la Innovación. La industria controla miles de millones del financiamiento europeo para la investigación, no da prioridad al interés público McArdle J, Tansey R 21 Los conflictos de interés de los editores de revistas oncológicas Salud y Fármacos 22 Pagos de la industria a oncólogos académicos con relación a su salario Salud y Fármacos 23 Las asociaciones médicas estadounidenses y la industria Salud y Fármacos 23 Crítica a las Buenas Guías de Publicación de las Revistas Médicas Salud y Fármacos 24 ¿Es ético que las empresas farmacéuticas vendan los medicamentos de venta con receta a los consumidores? Salud y Fármacos 26 Los grupos de defensa de los pacientes con patrocinio de la industria no deberían participar en política pública Salud y Fármacos 27 Cómo mejorar las declaraciones de conflictos de interés en las revistas científicas Salud y Fármacos 28 Listas de verificación para detectar posibles revistas biomédicas depredadoras: una revisión sistemática Cukier S, Helal L, Rice DB et al. 30 Judicialización de la salud y medicalización: análisis de las Guías del Consejo Nacional de Justicia Marques A, Rocha C, Asensi F, Monnerat D 31 Importancia, definición y conflictos de la autoría en publicaciones científicas Albarracin MLG, Castro CM, Chaparro PE. 31 Circulación de información sobre medicamentos y otras sustancias para aumentar el rendimiento cognitivo: un estudio de un blog brasileño (2015-2017) Pereira de Castro B, Reis Brandão E 31 Entrevistas El peligro de acelerar los ensayos clínicos durante la pandemia de coronavirus 31 Integridad de la Ciencia y de las Publicaciones Cuando las noticias anuncian resultados preliminares sobre Covid-19 hay que incluir advertencias fuertes 34 Receta para informar: cómo investigar los conflictos de interés de los profesores 37 El Lancet y el New England Journal of Medicine retractan estudios sobre Covid 19 que utilizaban datos de Surgisphere 41 Conducta de la industria Fabricantes de medicamentos promocionan las vacunas contra Covid-19 para restaurar su imagen pública 47 Empresa farmacéutica de genéricos admite fijar los precios de un medicamento contra el colesterol muy utilizado 49 Bioeticista alerta sobre tratamiento de celulas madres sin probar y sin licencia para Covid-19 50 AbbVie permite que se hagan versiones genéricas de Kaletra en todo el mundo 50 Las ventas de Amgen cayeron en 2019. Entonces, ¿por qué subieron el sueldo de su CEO Bradway em más de US$1millón? 51 Bayer. Cerca de 1M de euros donados por Bayer para luchar contra el Covid-19 51 Bristol- Myers Squibb. Versiones asequibles del medicamento contra la hepatitis C daclatasvir pronto estarán disponibles en otros países 52 Sobornos de Insys y la epidemia de opioides 53 El 27 de mayo de 2020, los ejecutivos de Moderna ya habían ganado millones de dólares 54 Mylan renuncia a los derechos exclusivos de distribución de una posible terapia contra Covid-19 en EE UU 55 El precio de la cloroquina y la epidemia de coronavirus 56 Sanofi donará 100 millones de dosis de hidroxicloroquina a 50 países. 56 Teva dona 390.000 dosis de hidroxicloroquina para probar su eficacia contra el Covid-19 56 Conflictos de Interés Grupos que se oponen a los medicamentos asequibles contra el coronavirus reciben contribuciones de las grandes farmacéuticas 57 Stephen Hahn, de la FDA, ayudó personalmente a un médico a preparar un ensayo con hidroxicloroquina - informe 58 Los conflictos de interés de altos funcionarios de la FDA les obligan a recusarse de la aprobación de vacunas Covid 19 58 Los senadores que lideraron la reforma de patentes para favorecer a la industria farmacéutica son los que más dinero reciben de las empresas farmacéuticas 60 Publicidad y Promoción Las cárceles y la promoción de medicamentos 62 La Asociación Americana de Cardiología (AHA) pone fin a la promoción de 'aspirina infantil' que Bayer hace en las farmacias 63 Las empresas farmacéuticas mejor calificadas en las redes sociales 64 Adulteraciones y Falsificaciones La pandemia de Covid aumenta las posibilidades de que los otros medicamentos que Ud. tiene no le sirvan 65 Derecho Litigación y Multas La Evolución de la Jurisprudencia en Materia de Salud en Argentina 70 La Judicialización del Derecho a la Salud 70 Primeras sanciones contra compañías por escasez de fármacos en Francia 70 Las patentes de Humira (Abbie) 71 Los tribunales anulan una patente de Biogen 71 La victoria de Bristol-Myers sobre Gilead por la patente en EE UU subió a US$1.200 millones 71 Inovio. Una demanda evidencia que la propiedad intelectual está frenando la producción de un candidato a vacuna contra Covid-19 que CEPI y la Fundación Gates financiar 72 Johnson & Johnson enfrenta una demanda por supuestamente haber ocultado los efectos adversos de Elmiron 74 La pelea entre las dos empresas Merck 75 Las empresas de genéricos y la fijación de precios 75 Novartis Hellas S.A.C.I. y Alcon Pte Ltd acuerdan pagar más de US$233 millones, en conjunto, para resolver casos penales por violar la FCPA. Novartis AG, Novartis Hellas S.A.C.I. y Alcon Pte Ltd acuerdan pagar más de US$345 millones en conjunto para resolver asuntos de FCPA con el gobierno 76 PixarBio. El fundador de la Biotech que dijo que su analgésico reemplazaría a los opioids fue sentenciado a 7 años de prisión 77 Regeneron y los pacientes de Medicare 78 La Corte Suprema del Reino Unido anula las patentes de Regeneron y abre la puerta a Kymab 78 Lucha de patentes entre Teva y Eli lilly por medicamento contra la migraña 79 Coalición de fiscales generales de EE UU demandan a fabricantes de genéricos por subir los precios 79 Allergan y patentes fraudulentas 80 Multas por no aportar información sobre los precios de los medicamentos 81 Tribunal Federal emite una orden de restricción temporal contra un hombre que ofrece tratamientos fraudulentos contra el coronavirus 81 Según una denuncia, el destituido director de BARDA rechazó las afirmaciones sobre la cloroquina y por ello se enfrentó a represalias 82 Jefe de empresa farmacéutica de origen indio no puede ocupar cargos directivos en el Reino Unido por haber fijado precios 83 Boletín Fármacos: Ética y Derecho 2020; 23 (3) Investigaciones COVID-19 y remdesivir: la construcción de un éxito de ventas durante una pandemia Ugalde A, Reyes A, Homedes N Objetivos: Entender el proceso decisorio de Gilead para determinar el precio de remdesivir y sus relaciones con el Conclusiones: Gilead ha aprovechado la pandemia y el apoyo de gobierno de Estados Unidos para conseguir sus objetivos Estados Unido para crear un mercado global para su económicos y mejorar su prestigio. medicamento que dadas las características del COVID-19 puede generar un gran margen de ganancia.
Load more

Recommended publications
  • Preparedness: Responding to Biological Attacks, Pandemics, and Emerging Infec- Tious Disease Outbreaks
    THE STATE OF U.S. PUBLIC HEALTH BIO- PREPAREDNESS: RESPONDING TO BIOLOGICAL ATTACKS, PANDEMICS, AND EMERGING INFEC- TIOUS DISEASE OUTBREAKS HEARING BEFORE THE SUBCOMMITTEE ON OVERSIGHT AND INVESTIGATIONS OF THE COMMITTEE ON ENERGY AND COMMERCE HOUSE OF REPRESENTATIVES ONE HUNDRED FIFTEENTH CONGRESS SECOND SESSION FRIDAY, JUNE 15, 2018 Serial No. 115–140 ( Printed for the use of the Committee on Energy and Commerce energycommerce.house.gov U.S. GOVERNMENT PUBLISHING OFFICE 35–127 WASHINGTON : 2019 VerDate Nov 24 2008 13:47 Feb 28, 2019 Jkt 037690 PO 00000 Frm 00001 Fmt 5011 Sfmt 5011 U:\MY DOCS\HEARINGS 115\HEARINGS\115-140 CHRIS COMMITTEE ON ENERGY AND COMMERCE GREG WALDEN, Oregon Chairman JOE BARTON, Texas FRANK PALLONE, JR., New Jersey Vice Chairman Ranking Member FRED UPTON, Michigan BOBBY L. RUSH, Illinois JOHN SHIMKUS, Illinois ANNA G. ESHOO, California MICHAEL C. BURGESS, Texas ELIOT L. ENGEL, New York MARSHA BLACKBURN, Tennessee GENE GREEN, Texas STEVE SCALISE, Louisiana DIANA DEGETTE, Colorado ROBERT E. LATTA, Ohio MICHAEL F. DOYLE, Pennsylvania CATHY MCMORRIS RODGERS, Washington JANICE D. SCHAKOWSKY, Illinois GREGG HARPER, Mississippi G.K. BUTTERFIELD, North Carolina LEONARD LANCE, New Jersey DORIS O. MATSUI, California BRETT GUTHRIE, Kentucky KATHY CASTOR, Florida PETE OLSON, Texas JOHN P. SARBANES, Maryland DAVID B. MCKINLEY, West Virginia JERRY MCNERNEY, California ADAM KINZINGER, Illinois PETER WELCH, Vermont H. MORGAN GRIFFITH, Virginia BEN RAY LUJA´ N, New Mexico GUS M. BILIRAKIS, Florida PAUL TONKO, New York BILL JOHNSON, Ohio YVETTE D. CLARKE, New York BILLY LONG, Missouri DAVID LOEBSACK, Iowa LARRY BUCSHON, Indiana KURT SCHRADER, Oregon BILL FLORES, Texas JOSEPH P.
    [Show full text]
  • Biden-Harris Transition Announces COVID-19 Advisory Board
    BIDEN-HARRIS TRANSITION The President-Elect The Vice President-Elect Priorities Transition Español NOVEMBER 09, 2020 PRESS RELEASES Biden-Harris Transition Announces COVID-19 Advisory Board Leading Public Health and Scientific Experts to Advise the Transition on COVID-19 Response WASHINGTON – Today, the Biden-Harris Transition announced the formation of the Transition COVID-19 Advisory Board, a team of leading public health experts who will advise President-elect Biden, Vice President-elect Harris, and the Transition’s COVID-19 staff. The Transition COVID-19 Advisory Board will be led by co-chairs Dr. David Kessler, Dr. Vivek Murthy, and Dr. Marcella Nunez-Smith. Dr. Beth Cameron and Dr. Rebecca Katz are serving as advisors to the Transition on COVID-19 and will work closely with the Advisory Board. “Dealing with the coronavirus pandemic is one of the most important battles our administration will face, and I will be informed by science and by experts,” said President-elect Biden. “The advisory board will help shape my approach to managing the surge in reported infections; ensuring vaccines are safe, effective, and distributed efficiently, equitably, and free; and protecting at-risk populations.” New cases are rising in at least 40 states, with more than 9.3 million total infections and more than 236,000 deaths. President-elect Biden has pledged to bring leadership to the COVID pandemic, which continues to claim thousands of lives each week, by curbing the spread of the disease, providing free treatment to those in need, and elevating the voices of scientists and public health experts. The COVID-19 Advisory Board will help guide the Biden-Harris Transition in planning for the President-elect’s robust federal response.
    [Show full text]
  • Bio's Virtual Summit Advances Medical Countermeasure
    BIO’S VIRTUAL SUMMIT ADVANCES MEDICAL COUNTERMEASURE PARTNERSHIPS FOR COVID-19 Launches Ongoing Initiative to Accelerate and Coordinate Development of Drugs, Vaccines, Preventives, and Diagnostics On March 24-25, 2020, BIO virtually convened more than 500 leaders from across industry, government, academia, and NGOs to assess the state of the pandemic and accelerate medical countermeasure solutions for COVID-19. BIO CEO Jim Greenwood and Dr. George Scangos, CEO of Vir, hosted the two-day summit to identify pressing technical, funding, regulatory and policy challenges, and enable BIO to catalyze cross- industry collaborations and public-private partnerships to advance development of medical countermeasures. Participants heard from key government officials, including Ambassador Deborah Birx, White House Coronavirus Response Coordinator, Dr. Robert Kadlec, HHS Assistant Secretary for Preparedness and Response, and Dr. Rick Bright, Director, Biomedical Advanced Research and Development Authority. KEY FINDINGS Based on Summit discussion, BIO identified the following critical needs and concerns: Successful development efforts will require the federal government to facilitate sharing of all relevant scientific and epidemiologic data and information as quickly and efficiently as possible. Many promising solutions will emerge from small and mid-sized companies and research laboratories, but these entities will likely have difficulty navigating the complex government contracting and regulatory bureaucracy; real-time assistance is needed. Early and rapid decisions from government funders will be essential to support immediate research, development, and clinical trial activity in order to identify the most promising candidates for further R&D and collaboration. Regulatory, advisory, and reimbursement authorities must be involved with requirement-setting and decision-making early on to prevent bottlenecks and downstream delays.
    [Show full text]
  • Key Global Health Positions and Officials in the U.S. Government
    January 2019 | Fact Sheet Key Global Health Positions and Officials in the U.S. Government Position Official WHITE HOUSE/EXECUTIVE OFFICE OF THE PRESIDENT Assistant to the President for National Security Affairs/National Security Advisor, National Security John Bolton Council (NSC) Senior Director for Weapons of Mass Destruction and Biodefense, NSC Tim Morrison Director for Medical and Biodefense Preparedness Policy, NSC Luciana Borio Director for Countering Biological Threats, NSC Hillary Carter Director for Global Health and International Development, NSC Peter Mamacos Special Assistant to the President; Senior Director for International Organizations and Alliances, Erin Walsh NSC Director, Office of Management and Budget (OMB) Mick Mulvaney Associate Director for National Security Programs, OMB Robert Blair Deputy Associate Director, International Affairs Division, National Security Programs, OMB Robert Fairweather Chief, Economic Affairs Branch, International Affairs Division, National Security Programs, OMB Fouad Saad Program Examiner, International Affairs Division, National Security Programs, OMB Will Cole Associate Director, Health Programs, OMB Joe Grogan Deputy Associate Director, Health Division, Health Programs, OMB Tom Reilly Chief, Public Health Branch, Health Programs, OMB Marc Garufi Program Examiner, Public Health Branch, Health Programs, OMB Nicholas Burton U.S. Trade Representative, Office of the United States Trade Representative (USTR) Robert Lighthizer Deputy U.S. Trade Representative, USTR C.J. Mahoney Assistant
    [Show full text]
  • May Your Drug Price Be Evergreen
    Journal of Law and the Biosciences, 590–647 doi:10.1093/jlb/lsy022 Advance Access Publication 7 December 2018 Original Article May your drug price be evergreen ∗,1 Robin Feldman Downloaded from https://academic.oup.com/jlb/article/5/3/590/5232981 by Elsevier user on 30 October 2020 Hastings College of the Law, University of California, 200 McAllister St. San Francisco, CA 94102, USA Corresponding author. E-mail: [email protected] ABSTRACT Presenting the first comprehensive study of evergreening, this article ex- amines the extent to which evergreening behavior—which can be defined as artificially extending the protection cliff—may contribute to theprob- lem. The author analyses all drugs on the market between 2005 and 2015, combing through 60,000 data points to examine every instance in which a company added a new patent or exclusivity. The results show a startling departure from the classic conceptualization of intellectual property pro- tection for pharmaceuticals. Rather than creating new medicines, pharma- ceutical companies are largely recycling and repurposing old ones. Specifi- cally, 78% of the drugs associated with new patents were not new drugs, but ∗ Robin Feldman is the Arthur J. Goldberg Distinguished Professor of Law and Director of the Institute for Innovation Law at the University of California Hastings. Her most recent books in the life sciences are Drug Wars (Cambridge) and Rethinking Patent Law (Harvard). Professor Feldman also has published more than 50 articles in law journals including at Harvard, Yale, and Stanford, as well as in the American Economic Review and the New England Journal of Medicine. Professor Feldman’s empirical work has been cited by the White House and numerous federal agencies.
    [Show full text]
  • Coalition for Epidemic Preparedness Innovations New Vaccines for a Safer World
    Coalition for Epidemic Preparedness Innovations New vaccines for a safer world Frederik Kristensen DCVMN Annual Meeting 25 October 2016 FOUNDING PARTNERS The challenge of epidemics Calls for global action CEPI - January - June Task Team Interim CEO High Level Task Team Leadership Meeting, Oslo appointed Meeting Tele- Group Meeting 6-7 April and constituted Davos conferences Washington DC Business Plan 21 January 17 May presented to stakeholders CEPI - July - September UNGA side Core Group First CEPI G7 Health event on health and CEPI soft interim board ministers’ side emergencies, Leadership launch meeting event, NY, Group Tele- Media London, Kobe, 19 September conferences coverage 31 August 10 September Challenges The pipeline is weak for most emerging infectious 1 diseases characterized by lack of market incentives Unilateral, uncoordinated government efforts to 2 fund R&D preparedness are inefficient and unsustainable in addressing global epidemic risks Clinical & regulatory pathways are not easily 3 adaptable to epidemic contexts Incentives are lacking to motivate 4 greater industry engagement Vaccine pipelines 45 40 35 30 25 20 15 10 5 0 Academic Government agency Biotech MNC Non-profits Preclinical Phase I Phase II Phase II/III Phase III Opportunities The Ebola momentum: vaccines are a feasible strategy, 1 despite a risky development pathway The Ebola momentum: it is possible to advance the 2 clinical development of safe and effective vaccines against EIDs in an emergency R&D actors supporting EID vaccine pipelines: 3 government health research agencies, academic research institutions, biotechs, vaccine manufacturers, and non-profits Manufacturing capability and capacity for vaccines has 4 always been a critical bottle-neck in epidemic events.
    [Show full text]
  • OP Ed: Another Victim of the Coronavirus: TRUTH (And a Not-To-Forget Lesson for People in Our Business)
    OP Ed: Another Victim Of The Coronavirus: TRUTH (And a Not-To-Forget Lesson For People In Our Business) Arthur Solomon, Public Relations Consultant The deadly coronavirus hates people. It has separated people from their families. It has separated people from their friends. It has caused massive unemployment. It frightens people. It is also responsible for an increase in hate messages on social media, targeting all minority populations, ranging from African-Americans, to Asian-Americans to religious Americans who practice Orthodox Judaism and to Jews who don’t. It has destroyed our way of living. The virus makes people very ill. Worst of all it kills people. But there is also a victim that was only made possible with the assistance of humans – TRUTH. President Trump’s revisionist remarks about the coronavirus, which is happening as I write this, on April 26, continues. The result: For many Americans is there is no TRUTH. And politics and the media have played a large part in aiding the virus to put TRUTH on life support. While TRUTH had been ill since January, it took a sudden turn for the worse in the U.S. on February 28, during a rally in South Carolina, when President Trump described the virus as a Democratic “hoax.” Other presidential remarks like saying, anyone who wants a test can get one; there are plenty of PPE supplies; doctors and nurses are hording them; we have the situation under control; his hawking of medicines for people infected with the disease as if he was a medical scientist, and his contradictory remarks about blaming the coronavirus on China, to name a few of the president’s comments, all added to put TRUTH in a grave condition.
    [Show full text]
  • AKDN COVID-19 Policy Digest Bulletin #33 | Date: 16 November 2020 International Scientific Brief: Community Use of Cloth Mask
    1 AKDN COVID-19 Policy Digest Bulletin #33 | Date: 16 November 2020 International Scientific Brief: Community Use of Cloth Masks to Control the Spread of SARS-CoV-2 Centers for Disease Control and Prevention (CDC) https://www.cdc.gov/coronavirus/2019-ncov/more/masking-science-sars-cov2.html In a brief published on 10 November, the CDC recommends community use of masks, specifically non- valved multi-layer cloth masks, to prevent transmission of SARS-CoV-2. Masks are primarily intended to reduce the emission of virus-laden droplets (source control), which is especially relevant for asymptomatic or presymptomatic infected wearers who feel well and may be unaware of their infectiousness to others, and who are estimated to account for more than 50% of transmissions. Masks also help reduce inhalation of these droplets by the wearer (“filtration for personal protection”). The Johns Hopkins Center for Health Security explains that this guidance is noteworthy because masks can provide protection for the wearer as well, including the ability to filter “fine droplets and particles less than 10 micros.” Recent studies found that the filtration effect varied between masks and mask types, with multi-layer masks and mask types constructed with more densely woven material, preforming better than single-later masks made from lower thread count fabric. Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19 U.S. Food and Drug Administration (FDA) https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes- monoclonal-antibody-treatment-covid-19 The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) on 9 November, for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and paediatric patients.
    [Show full text]
  • Thomas Wood1 I. Introduction Microtransactions Are Generally
    ______________________________________________________________________________ ______________________________________________________________________________ RIGGING THE GAME: THE LEGALITY OF RANDOM CHANCE PURCHASES (“LOOT BOXES”) UNDER CURRENT MASSACHUSETTS GAMBLING LAW Thomas Wood1 I. Introduction Microtransactions are generally defined as any additional payment made in a video game after the customer makes an original purchase.2 Over time, microtransactions have increased in prominence and are featured today in many free-to-play mobile games.3 However, some video game developers, to the outrage of consumers, have decided to include microtransactions in PC and console games, which already require an upfront $60 retail payment.4 Consumer advocacy groups have increasingly criticized Microtransactions as unfair to 1 J.D. Candidate, Suffolk University Law School, 2020; B.S. in Criminal Justice and minor in Political Science, University of Massachusetts Lowell, 2017. Thomas Wood can be reached at [email protected]. 2 See Eddie Makuch, Microtransactions, Explained: Here's What You Need To Know, GAMESPOT (Nov. 20, 2018), archived at https://perma.cc/TUX6-D9WL (defining microtransactions as “anything you pay extra for in a video game outside of the initial purchase”); see also Microtransaction, URBAN DICTIONARY (Oct. 29, 2018), archived at https://perma.cc/XS7R-Z4TT (describing microtransactions sarcastically as a “method that game companies use to make the consumer’s wallets burn” and “the cancer of modern gaming”). 3 See Mike Williams, The Harsh History of Gaming Microtransactions: From Horse Armor to Loot Boxes, USGAMER (Oct. 11, 2017), archived at https://perma.cc/PEY6-SFL2 (outlining how the loot box model was originally created in Asia through MMOs and free-to-play games); see also Loot Boxes Games, GIANT BOMB (Nov.
    [Show full text]
  • Download Preprint
    Recommendations from the Reducing the Inadvertent Spread of Retracted Science: Shaping a Research and Implementation Agenda Project Jodi Schneider*, Nathan D. Woods, Randi Proescholdt, Yuanxi Fu, and the RISRS Team July 2021 *Corresponding author: [email protected] and [email protected] Table of Contents EXECUTIVE SUMMARY 3 Recommendations 4 INTRODUCTION 5 RISRS Project Goals and Assumptions 6 Framing the Problem 8 Scope of this Document 9 THE RISRS PROCESS 10 Scoping Literature Review 10 Interviews 11 Workshop, Dissemination, and Implementation 11 LITERATURE REVIEW AND CURRENT AWARENESS 11 Reasons for Retraction 11 Formats and Types of Retraction 13 Field Variation 15 Continued Citation of Retracted Papers: What Went Wrong? 20 Visibility of Retraction Status 24 Inconsistent Retraction Metadata 25 Quality of Retraction Notices 26 Literature Review Conclusions 28 DEFINING PROBLEMS AND OPPORTUNITIES 29 PROBLEMS AND OPPORTUNITIES DESCRIBED BY THE EMPIRICAL LITERATURE ON RETRACTION 29 Problem Themes Described by the Empirical Literature on Retraction 30 Opportunity Themes Described by the Empirical Literature on Retraction 32 Problem Definition Described by the Empirical Literature on Retraction 35 THEMES FROM STAKEHOLDER INTERVIEWS 36 Problem Frameworks based on Stakeholder Interviews 36 Contentious Themes based on Stakeholder Interviews 38 The Purpose of Retraction According to Stakeholder Interviews 38 Changing the Scholarly Record 39 The Harms of Retraction According to Stakeholder Interviews 39 The Character of Reform According to Stakeholder Interviews 40 SYNTHESIZING THE PROBLEMS AND OPPORTUNITIES 41 Aligning Opportunity Pathways 41 Defining the Scale and Scope of the Problem 42 RECOMMENDATIONS 43 1. Develop a Systematic Cross-industry Approach to Ensure the Public Availability of Consistent, Standardized, Interoperable, and Timely Information about Retractions.
    [Show full text]
  • Integrating Research Integrity Into the History of Science
    HOS0010.1177/0073275320952257History of ScienceMody et al. 952257research-article2020 Introduction HOS History of Science 2020, Vol. 58(4) 369 –385 Integrating research integrity © The Author(s) 2020 into the history of science https://doi.org/10.1177/0073275320952257Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/0073275320952257 journals.sagepub.com/home/hos Cyrus C. M. Mody Maastricht University, Netherlands H. Otto Sibum Uppsala University, Sweden Lissa L. Roberts University of Twente, Netherlands Abstract This introductory essay frames our special issue by discussing how attention to the history of research integrity and fraud can stimulate new historical and methodological insights of broader import to historians of science. Keywords Scientific integrity, fraud, scientific values, scientific controversies, history of science The politics of integrity In the companion introductory essay to this special issue, readers encounter the accusa- tions and counter-accusations surrounding Didier Raoult.1 Controversial figures like Raoult make compelling reading. The lurid details of his appearance, provocative lan- guage, past defiance of conventional wisdom, current climate denialism, and compli- cated relationship with his staff draw attention and generate doubts about the integrity of 1. Lissa L. Roberts, H. Otto Sibum and Cyrus C. M. Mody, “Integrating the History of Science into Broader Discussions of Research Integrity and Fraud,” History of Science 58 (2020): 354–68. Corresponding author: Lissa L. Roberts, University
    [Show full text]
  • Ethics, Transparency and Independency in Scientific Publications
    Dermatology and Cosmetology International Journal Opinion Ethics, Transparency and Independency in Scientific Publications. An Appeal to the International Community Torello Lotti* Department of Dermatology, University of Rome G Marconi, Italy Opinion 2. Evidence - The Editor of the Millennium Issue of the Archives of Derma our Discipline and to envision future developments. On January tology asked few opinion leaders to assess the state of the Art of 1st 3. Repetition always available - 4. Experimental observation for testing hypotheses 2000, Volume 136, N. 1 of the JAMA Dermatology was available for saluting the New Millennium. I contributed with a page enti the skin” in which I tried to identify the “Diseases of Dermatology” 5. Conclusions based on the experimental evidence tled “The Renaissance of Dermatology: selected concepts beyond 6. Critical analysis for verification illnesses pandemics and even death of our Discipline.1 One of my and, more in general, the “Disease of Science” possibly bringing to 7. Critical exposure to scrutiny, peer review and assessment spurn, to disdain and to loathe pseudoscience. I proudly confess to be part of the “Family of Science” and to main concerns was the reliability of the results of the double blind - randomized clinical trials i.e. touching bases of the Evidence-Based The sight or the smell of pseudoscience makes me sick. I’m not Medicine (EBM), Good Clinical Practice and Ethics in Scientific Pub - alone. According to Michael Gordin “no one in the history of the lication and Ethics, Transparency and Independency of Scientific entists or at least we think so. Publications.Pseudoscience and science: who are you? world has ever self-identified as a pseudoscientist”.
    [Show full text]